安旭生物
(688075)
| 流通市值：48.37亿 | | | 总市值：48.37亿 |
| 流通股本：1.27亿 | | | 总股本：1.27亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 441,570,489.4 | 467,922,697.94 | 190,499,987.45 | 652,389,775.61 |
| 应收票据及应收账款 | 283,512,930.5 | 203,690,596.91 | 253,603,712.29 | 198,083,309.89 |
| 其中：应收票据 | - | - | 108,000 | - |
| 应收账款 | 283,512,930.5 | 203,690,596.91 | 253,495,712.29 | 198,083,309.89 |
| 预付款项 | 27,003,838.75 | 20,146,454.23 | 47,962,649.55 | 38,116,505.03 |
| 其他应收款合计 | 6,569,943.12 | 7,995,596.61 | 13,102,767.43 | 13,659,094.29 |
| 存货 | 143,539,795.97 | 147,167,029.08 | 163,295,574.05 | 171,840,366.1 |
| 其他流动资产 | 2,538,075,456.09 | 2,387,032,579.9 | 2,334,528,836.5 | 2,205,705,210.8 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 4,847,904,481.23 | 4,769,982,927.28 | 4,838,943,771.1 | 4,835,904,083.63 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 |
| 固定资产 | 614,098,691.12 | 624,938,284.16 | 631,795,241.75 | 640,580,762.41 |
| 在建工程 | 141,179,935.14 | 124,715,040.55 | 67,602,163.83 | 58,177,038.54 |
| 使用权资产 | 6,041,642.98 | 6,943,852.56 | 8,288,461.58 | 9,378,853.48 |
| 无形资产 | 44,639,687.24 | 45,776,759.73 | 45,511,971.41 | 51,609,005.72 |
| 长期待摊费用 | 16,740,250.95 | 18,076,978.1 | 17,106,889.71 | 18,491,882.23 |
| 递延所得税资产 | 160,084,062.25 | 161,112,486.85 | 166,449,252.24 | 162,311,021.85 |
| 其他非流动资产 | 8,306,405.7 | 11,764,566.04 | 15,304,723.15 | 14,000,891.23 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 997,090,675.38 | 999,327,967.99 | 958,058,703.67 | 960,549,455.46 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,844,995,156.61 | 5,769,310,895.27 | 5,797,002,474.77 | 5,796,453,539.09 |
| 流动负债: | | | | |
| 短期借款 | - | 280,000 | 1,000,000 | 1,000,000 |
| 衍生金融负债 | - | - | 19,979,778.89 | 21,033,251.91 |
| 应付票据及应付账款 | 434,550,664.81 | 401,509,274.65 | 373,225,124.91 | 392,024,862.48 |
| 其中：应付票据 | 64,052,998.33 | 73,836,769.25 | 55,767,385.44 | 41,531,518.41 |
| 应付账款 | 370,497,666.48 | 327,672,505.4 | 317,457,739.47 | 350,493,344.07 |
| 合同负债 | 22,620,620.08 | 17,832,868.21 | 23,003,188.22 | 11,629,564.29 |
| 应付职工薪酬 | 13,795,559.62 | 19,864,855.74 | 6,846,780.8 | 7,686,941.34 |
| 应交税费 | 7,397,722.87 | 18,394,720.23 | 5,571,658.17 | 11,480,207.72 |
| 其他应付款合计 | 19,580,759.85 | 13,167,337.5 | 102,956,824.87 | 66,450,719.84 |
| 应付股利 | - | - | 50,833,122 | 50,833,122 |
| 一年内到期的非流动负债 | 82,710.58 | 3,531,596.07 | 4,493,693.83 | 4,041,995.94 |
| 其他流动负债 | - | 734,362.16 | 2,791,828.81 | 484,565.18 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 498,028,037.81 | 475,315,014.56 | 539,868,878.5 | 515,832,108.7 |
| 非流动负债: | | | | |
| 租赁负债 | 6,069,710.53 | 4,346,367.09 | 4,016,051.68 | 6,275,621.84 |
| 预计负债 | 27,825,850.02 | 8,104,370.02 | 30,610,482.68 | 30,938,523.79 |
| 递延收益 | 9,732,064.91 | 10,572,373.53 | 3,337,127.27 | 3,337,127.27 |
| 递延所得税负债 | 71,220,590.55 | 71,185,483.29 | 71,736,895.92 | 68,798,665.53 |
| 其他非流动负债 | - | - | - | 0 |
| 非流动负债平衡项目 | -0.01 | 0 | 0 | 0 |
| 非流动负债合计 | 114,848,216 | 94,208,593.93 | 109,700,557.55 | 109,349,938.43 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 612,876,253.81 | 569,523,608.49 | 649,569,436.05 | 625,182,047.13 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 127,082,805 | 127,082,805 | 127,082,805 | 127,082,805 |
| 资本公积 | 1,050,333,724.27 | 1,050,333,724.27 | 1,050,333,724.27 | 1,050,333,724.27 |
| 其他综合收益 | 9,475,976.9 | 11,371,779.31 | 15,506,208.25 | 8,791,495.62 |
| 盈余公积 | 62,069,454.51 | 62,069,454.51 | 48,584,214.59 | 48,584,214.59 |
| 未分配利润 | 3,986,771,044.27 | 3,952,741,425.5 | 3,909,715,059.55 | 3,940,083,495.43 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0.01 | 0 |
| 归属于母公司股东权益合计 | 5,235,733,004.95 | 5,203,599,188.59 | 5,151,222,011.67 | 5,174,875,734.91 |
| 少数股东权益 | -3,614,102.15 | -3,811,901.81 | -3,788,972.94 | -3,604,242.95 |
| 股东权益平衡项目 | 0 | 0 | -0.01 | 0 |
| 股东权益合计 | 5,232,118,902.8 | 5,199,787,286.78 | 5,147,433,038.72 | 5,171,271,491.96 |
| 负债和股东权益合计 | 5,844,995,156.61 | 5,769,310,895.27 | 5,797,002,474.77 | 5,796,453,539.09 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |